» Articles » PMID: 38993827

C-X-C Motif Chemokine Ligand 12-C-X-C Chemokine Receptor Type 4 Signaling Axis in Cancer and the Development of Chemotherapeutic Molecules

Overview
Journal Tzu Chi Med J
Specialty General Medicine
Date 2024 Jul 12
PMID 38993827
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokines are small, secreted cytokines crucial in the regulation of a variety of cell functions. The binding of chemokine C-X-C motif chemokine ligand 12 (CXCL12) (stromal cell-derived factor 1) to a G-protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) triggers downstream signaling pathways with effects on cell survival, proliferation, chemotaxis, migration, and gene expression. Intensive and extensive investigations have provided evidence suggesting that the CXCL12-CXCR4 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, as well as in creating tumor microenvironment, thus implying that this axis is a potential target for the development of cancer therapies. The structures of CXCL12 and CXCR4 have been resolved with experimental methods such as X-ray crystallography, NMR, or cryo-EM. Therefore, it is possible to apply structure-based computational approaches to discover, design, and modify therapeutic molecules for cancer treatments. Here, we summarize the current understanding of the roles played by the CXCL12-CXCR4 signaling axis in cellular functions linking to cancer progression and metastasis. This review also provides an introduction to protein structures of CXCL12 and CXCR4 and the application of computer simulation and analysis in understanding CXCR4 activation and antagonist binding. Furthermore, examples of strategies and current progress in CXCL12-CXCR4 axis-targeted development of therapeutic anticancer inhibitors are discussed.

Citing Articles

Immunoexpression of CXCL12 and CXCR4 in oral tongue squamous cell carcinoma of young and older patients.

de Lucena Morais D, de Sena L, Cunha J, de Mendonca E, Alves P, Nonaka C Eur Arch Otorhinolaryngol. 2024; .

PMID: 39613853 DOI: 10.1007/s00405-024-09106-w.

References
1.
Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin B, Stemmer S . BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020; 26(6):878-885. DOI: 10.1038/s41591-020-0880-x. View

2.
Peng S, Zhang X, Paul D, Kays L, Gough W, Stewart J . Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2014; 14(2):480-90. DOI: 10.1158/1535-7163.MCT-14-0850. View

3.
Kawatkar S, Yan M, Gevariya H, Lim M, Eisold S, Zhu X . Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists. Exp Biol Med (Maywood). 2011; 236(7):844-50. PMC: 3900290. DOI: 10.1258/ebm.2011.010345. View

4.
Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B . Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem. 1998; 273(12):7024-9. DOI: 10.1074/jbc.273.12.7024. View

5.
Contento R, Molon B, Boularan C, Pozzan T, Manes S, Marullo S . CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci U S A. 2008; 105(29):10101-6. PMC: 2481367. DOI: 10.1073/pnas.0804286105. View